search
Back to results

pBFS-guided Noninvasive Neuromodulation for Pre-school Children With ASD

Primary Purpose

Autism Spectrum Disorder

Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
active iTBS
active iTBS
sham iTBS
sham iTBS
Sponsored by
Changping Laboratory
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Autism Spectrum Disorder focused on measuring TMS, ASD, fMRI, personalized medicine

Eligibility Criteria

30 Months - 6 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria: 2.5-6 years old Have the diagnosis of autism spectrum disorder ADOS-2 score is higher than the ASD cut-offs Capacity to follow the study procedures, including fMRI scan under sedation, assessment, and rehabilitation training Participant's parents or other legal guardians give informed consent Exclusion Criteria: Current or history of psychotic disorders, such as schizophrenia, schizoaffective disorder, bipolar disorder Severe self-injury or suicidal behavior presented in the last 1 year Severe visual, auditory, or motor disability that interferes with any study procedure Current, history or family history of epilepsy Known severe physical diseases, such as congenital heart defect, traumatic brain injury Metal implantations, which are contradicted by MRI or TMS, such as artificial cardiac pacemakers, stents, cochlear implants Received TMS, tCS, FUS, or other neuromodulation treatment in the last 3 months Currently participating in other clinical trials

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm 3

    Arm 4

    Arm Type

    Experimental

    Experimental

    Sham Comparator

    Sham Comparator

    Arm Label

    DLPFC group

    DMPFC group

    Sham to DLPFC group

    Sham to DMPFC group

    Arm Description

    Active iTBS will be delivered to the left DLPFC.

    Active iTBS will be delivered to the left DMPFC.

    Sham iTBS will be delivered to the left DLPFC.

    Sham iTBS will be delivered to the left DMPFC.

    Outcomes

    Primary Outcome Measures

    ADOS-2 SA change
    The social affect (SA) dimension score change of autism diagnostic observation scale, 2nd edition (ADOS-2) from baseline. Higher scores mean a worse outcome.

    Secondary Outcome Measures

    ADOS-2 total score change
    The total score change of autism diagnostic observation scale, 2nd edition (ADOS-2) from baseline. Higher scores mean a worse outcome.
    CBCL score change
    Score change of the child behavior checklist (CBCL) from baseline. Higher scores mean a worse outcome.

    Full Information

    First Posted
    September 4, 2023
    Last Updated
    September 4, 2023
    Sponsor
    Changping Laboratory
    Collaborators
    Henan Provincial People's Hospital
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT06031948
    Brief Title
    pBFS-guided Noninvasive Neuromodulation for Pre-school Children With ASD
    Official Title
    Personalized Brain Functional Sectors (pBFS) Guided Noninvasive Neuromodulation Treatment for Pre-school Children With Autism Spectrum Disorder (ASD): a Single-center, Double-blinded, Sham-Controlled, Randomized Clinical Trial Study
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    September 2023
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    October 1, 2023 (Anticipated)
    Primary Completion Date
    August 1, 2024 (Anticipated)
    Study Completion Date
    January 1, 2025 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Changping Laboratory
    Collaborators
    Henan Provincial People's Hospital

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No

    5. Study Description

    Brief Summary
    This randomized controlled trial aims to evaluate the efficacy and safeness of the pBFS-guided rTMS intervention for core symptom relief in pre-school children with autism spectrum disorder (ASD).
    Detailed Description
    Autism spectrum disorder is a neurodevelopmental disorder, begins early in life. Using the personalized brain functional sectors (pBFS) technology, investigators could precisely identify individualized brain function networks based on the functional MRI scan. For each participant, two personalised TMS intervention targets will be chosen by blinded researcher. One executive function network target is located in the dorsal lateral prefrontal cortex (DLPFC) , and the other social function network target is located in the dorsal medial prefrontal cortex (DMPFC). The participants will be equally randomized to the following four groups, active iTBS to the left DMPFC or the left DLPFC, and sham iTBS to either the left DMPFC or left DLPFC at a ratio of 2:2:1:1. Later analyses will combine the two sham groups as one control group. Each participant will receive 1800 pulse active or sham iTBS (100% RMT) in each session, 3 sessions daily, 5 days per week for 8 weeks, as well as background behavioral training between iTBS sessions. Pre-and post-treatment functional MRI data will be collected under sedation.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Autism Spectrum Disorder
    Keywords
    TMS, ASD, fMRI, personalized medicine

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Masking
    ParticipantCare ProviderInvestigatorOutcomes Assessor
    Allocation
    Randomized
    Enrollment
    50 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    DLPFC group
    Arm Type
    Experimental
    Arm Description
    Active iTBS will be delivered to the left DLPFC.
    Arm Title
    DMPFC group
    Arm Type
    Experimental
    Arm Description
    Active iTBS will be delivered to the left DMPFC.
    Arm Title
    Sham to DLPFC group
    Arm Type
    Sham Comparator
    Arm Description
    Sham iTBS will be delivered to the left DLPFC.
    Arm Title
    Sham to DMPFC group
    Arm Type
    Sham Comparator
    Arm Description
    Sham iTBS will be delivered to the left DMPFC.
    Intervention Type
    Device
    Intervention Name(s)
    active iTBS
    Intervention Description
    Each participant will receive 1800 pulse active iTBS (100% RMT) in each session, 3 sessions per day, 5 days per week for 8 weeks.
    Intervention Type
    Device
    Intervention Name(s)
    active iTBS
    Intervention Description
    Each participant will receive 1800 pulse active iTBS (100% RMT) in each session, 3 sessions per day, 5 days per week for 8 weeks.
    Intervention Type
    Device
    Intervention Name(s)
    sham iTBS
    Intervention Description
    Each participant will receive 1800 pulse sham iTBS (100% RMT) in each session, 3 sessions per day, 5 days per week for 8 weeks.
    Intervention Type
    Device
    Intervention Name(s)
    sham iTBS
    Intervention Description
    Each participant will receive 1800 pulse sham iTBS (100% RMT) in each session, 3 sessions per day, 5 days per week for 8 weeks.
    Primary Outcome Measure Information:
    Title
    ADOS-2 SA change
    Description
    The social affect (SA) dimension score change of autism diagnostic observation scale, 2nd edition (ADOS-2) from baseline. Higher scores mean a worse outcome.
    Time Frame
    Pre-treatment (baseline), immediately post-treatment
    Secondary Outcome Measure Information:
    Title
    ADOS-2 total score change
    Description
    The total score change of autism diagnostic observation scale, 2nd edition (ADOS-2) from baseline. Higher scores mean a worse outcome.
    Time Frame
    Pre-treatment (baseline), immediately post-treatment
    Title
    CBCL score change
    Description
    Score change of the child behavior checklist (CBCL) from baseline. Higher scores mean a worse outcome.
    Time Frame
    Pre-treatment (baseline), immediately post-treatment
    Other Pre-specified Outcome Measures:
    Title
    SCQ score change
    Description
    Score change of the Social Communication Questionnaire (SCQ) from baseline. Higher scores mean a worse outcome.
    Time Frame
    Pre-treatment (baseline), immediately post-treatment
    Title
    SRS-2 score change
    Description
    Score change of the Social Responsiveness Scale, 2nd edition (SRS-2) from baseline. Higher scores mean a worse outcome.
    Time Frame
    Pre-treatment (baseline), immediately post-treatment
    Title
    RBS-R score change
    Description
    Score change of the Repetitive Behavior Scale-Revised (RBS-R) from baseline. Higher scores mean a worse outcome.
    Time Frame
    Pre-treatment (baseline), immediately post-treatment

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    30 Months
    Maximum Age & Unit of Time
    6 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: 2.5-6 years old Have the diagnosis of autism spectrum disorder ADOS-2 score is higher than the ASD cut-offs Capacity to follow the study procedures, including fMRI scan under sedation, assessment, and rehabilitation training Participant's parents or other legal guardians give informed consent Exclusion Criteria: Current or history of psychotic disorders, such as schizophrenia, schizoaffective disorder, bipolar disorder Severe self-injury or suicidal behavior presented in the last 1 year Severe visual, auditory, or motor disability that interferes with any study procedure Current, history or family history of epilepsy Known severe physical diseases, such as congenital heart defect, traumatic brain injury Metal implantations, which are contradicted by MRI or TMS, such as artificial cardiac pacemakers, stents, cochlear implants Received TMS, tCS, FUS, or other neuromodulation treatment in the last 3 months Currently participating in other clinical trials
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Qi Liu, Ph.D.
    Phone
    010-80726688
    Email
    a0000153@cpl.ac.cn
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Hesheng Liu, Ph.D.
    Organizational Affiliation
    Changping Laboratory
    Official's Role
    Study Chair

    12. IPD Sharing Statement

    Learn more about this trial

    pBFS-guided Noninvasive Neuromodulation for Pre-school Children With ASD

    We'll reach out to this number within 24 hrs